ABOUT ijhrs


International Journal of Health and Rehabilitation Sciences

International Journal of Health and Rehabilitation Sciences
ISSN (online) : 2278-9030
ISSN (Print) : 2278-9014
ISSUES : 4/year
PUBLISHER : Rehabilitation Without Borders

ARTICLE TOOLS


Warning: Use of undefined constant mno - assumed 'mno' (this will throw an Error in a future version of PHP) in /home/ijhrs/public_html/index.php on line 60

Review Article 


Safety and Efficacy of Pharmacological Management of Agitation in Alzheimer’s Dementia - A Review

Anjali N Kalore, Dhananjay Medappa, Eukesh Ranjit, Sandeep S Nayak.

Cited by (2)

Abstract
Agitation is a common and distressful symptom in Alzheimer’s dementia. Pharmacological treatment is frequently needed when symptoms are moderate to severe. Basic etiology and pathogenesis of agitation is not well understood and this makes targeted pharmacotherapy challenging. Many drugs have been tried but FDA has not approved any drug for treatment and there is lack of consensus. We review the principles, indications and current Level I evidence on the safety and efficacy of various drugs used for treatment of agitation in Alzheimer’s Dementia. We find that newer drugs like citalopram and prazosin have greater efficacy and are better tolerated than antipsychotic medications.

Key words: Safety, Efficacy, Pharmacological Management, Agitation, Alzheimer’s Dementia


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Anjali N Kalore
Articles by Dhananjay Medappa
Articles by Eukesh Ranjit
Articles by Sandeep S Nayak
on Google
on Google Scholar


REFERENCES
1. Ropacki SA,Jeste DV: Epidemiology of and risk factors for psychosis of Alzheimer's disease: a review of 55 studies published from 1990 to 2003. Am J Psychiatry 2005; 162:2022-2030 [DOI via Crossref]    [Pubmed]   
2. Howard RJ, Juszczak E, Ballard CG, et al: Donepezil for the treatment of agitation in Alzheimer's disease. N Engl J Med 2007; 357:1382-1392 [DOI via Crossref]    [Pubmed]   
3. Lyketsos CG, Steinberg M, Tschanz JT, et al: Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry 2000; 157:708-714 [DOI via Crossref]   
4. Margallo-Lana M, Swann A, O'Brien J, et al: Prevalence and pharmacological management of behavioural and psychological symptoms amongst dementia sufferers living in care environments. Int J Geriatr Psychiatry 2001; 16:39-44 [DOI via Crossref]   
5. Hirono N, Mega MS, Dinov ID, et al: Left frontotemporal hypoperfusion is associated with aggression in patients with dementia. Arch Neurol 2000; 57:861-866 [DOI via Crossref]   
6. Tekin S, Mega MS, Masterman DM, et al: Orbitofrontal and anterior cingulate cortex neurofibrillary tangle burden is associated with agitation in Alzheimer disease. Ann Neurol 2001; 49:355-361 [DOI via Crossref]   
7. Everitt DE, Fields DR, Soumerai SS, et al: Resident behavior and staff distress in the nursing home. J Am Geriatr Soc 1991; 39:792-798 [DOI via Crossref]   
8. Hopkins MW,Libon DJ: Neuropsychological functioning of dementia patients with psychosis. Arch Clin Neuropsychol 2005; 20:771-783 [DOI via Crossref]    [Pubmed]   
9. Lopez OL, Wisniewski SR, Becker JT, et al: Psychiatric medication and abnormal behavior as predictors of progression in probable Alzheimer disease. Arch Neurol 1999; 56:1266-1272 [DOI via Crossref]   
10. Schneider LS, Pollock VE,Lyness SA: A metaanalysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc 1990; 38:553-563 [DOI via Crossref]   
11. Tune LE, Steele C,Cooper T: Neuroleptic drugs in the management of behavioral symptoms of Alzheimer's disease. Psychiatr Clin North Am 1991; 14:353-373 [Pubmed]   
12. Reilly JG, Ayis SA, Ferrier IN, et al: QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 2000; 355:1048-1052 [DOI via Crossref]   
13. Ballard C,Waite J: The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev 2006; CD003476 [Pubmed]   
14. Sink KM, Holden KF,Yaffe K: Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA 2005; 293:596-608 [DOI via Crossref]    [Pubmed]   
15. Schneider LS, Dagerman K,Insel PS: Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 2006; 14:191-210 [DOI via Crossref]    [Pubmed]   
16. Kindermann SS, Dolder CR, Bailey A, et al: Pharmacological treatment of psychosis and agitation in elderly patients with dementia: four decades of experience. Drugs Aging 2002; 19:257-276 [DOI via Crossref]   
17. Schneider LS, Tariot PN, Dagerman KS, et al: Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 2006; 355:1525-1538 [DOI via Crossref]    [Pubmed]   
18. Bech P, Larsen JK,Andersen J: The BPRS: psychometric developments. Psychopharmacol Bull 1988; 24:118-121 [Pubmed]   
19. Reisberg B, Auer SR,Monteiro IM: Behavioral pathology in Alzheimer's disease (BEHAVE-AD) rating scale. Int Psychogeriatr 1996; 8 Suppl 3:301-308; discussion 351-304
20. Cummings JL: The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology 1997; 48:S10-16 [DOI via Crossref]    [Pubmed]   
21. Herrmann N,Lanctôt KL: Do atypical antipsychotics cause stroke? CNS Drugs 2005; 19:91-103 [DOI via Crossref]    [Pubmed]   
22. Schneider LS, Dagerman KS,Insel P: Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005; 294:1934-1943 [DOI via Crossref]    [Pubmed]   
23. Trinh NH, Hoblyn J, Mohanty S, et al: Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA 2003; 289:210-216 [DOI via Crossref]   
24. Holmes C, Wilkinson D, Dean C, et al: The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 2004; 63:214-219 [DOI via Crossref]   
25. Ballard C, Margallo-Lana M, Juszczak E, et al: Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ 2005; 330:874 [DOI via Crossref]    [Pubmed]    [PMC Free Fulltext]   
26. Gauthier S, Feldman H, Hecker J, et al: Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. Int Psychogeriatr 2002; 14:389-404 [DOI via Crossref]   
27. Gauthier S, Wirth Y,Mobius HJ: Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. Int J Geriatr Psychiatry 2005; 20:459-464 [DOI via Crossref]    [Pubmed]   
28. McShane R, Areosa Sastre A,Minakaran N: Memantine for dementia. Cochrane Database Syst Rev 2006; CD003154 [DOI via Crossref]   
29. Gauthier S, Loft H,Cummings J: Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis. Int J Geriatr Psychiatry 2008; 23:537-545 [DOI via Crossref]    [Pubmed]   
30. Wilcock GK, Ballard CG, Cooper JA, et al: Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. J Clin Psychiatry 2008; 69:341-348 [DOI via Crossref]   
31. Fox C, Crugel M, Maidment I, et al: Efficacy of memantine for agitation in Alzheimer's dementia: a randomised double-blind placebo controlled trial. PLoS One 2012; 7:e35185 [DOI via Crossref]    [Pubmed]    [PMC Free Fulltext]   
32. Howard R, McShane R, Lindesay J, et al: Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med 2012; 366:893-903 [DOI via Crossref]    [Pubmed]   
33. Pollock BG, Mulsant BH, Rosen J, et al: Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry 2002; 159:460-465 [DOI via Crossref]   
34. Pollock BG, Mulsant BH, Rosen J, et al: A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. Am J Geriatr Psychiatry 2007; 15:942-952 [DOI via Crossref]    [Pubmed]   
35. Finkel SI, Mintzer JE, Dysken M, et al: A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil. Int J Geriatr Psychiatry 2004; 19:9-18 [DOI via Crossref]    [Pubmed]   
36. Teri L, Logsdon RG, Peskind E, et al: Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology 2000; 55:1271-1278 [DOI via Crossref]   
37. Tariot PN, Erb R, Podgorski CA, et al: Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry 1998; 155:54-61 [DOI via Crossref]   
38. Olin JT, Fox LS, Pawluczyk S, et al: A pilot randomized trial of carbamazepine for behavioral symptoms in treatment-resistant outpatients with Alzheimer disease. Am J Geriatr Psychiatry 2001; 9:400-405 [DOI via Crossref]   
39. Konovalov S, Muralee S,Tampi RR: Anticonvulsants for the treatment of behavioral and psychological symptoms of dementia: a literature review. Int Psychogeriatr 2008; 20:293-308 [DOI via Crossref]    [Pubmed]   
40. Sharp SI, Ballard CG, Chen CP, et al: Aggressive behavior and neuroleptic medication are associated with increased number of alpha1-adrenoceptors in patients with Alzheimer disease. Am J Geriatr Psychiatry 2007; 15:435-437 [DOI via Crossref]    [Pubmed]   
41. Wang LY, Shofer JB, Rohde K, et al: Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression. Am J Geriatr Psychiatry 2009; 17:744-751 [DOI via Crossref]    [Pubmed]    [PMC Free Fulltext]   

This Article Cited By the following articles

A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer’s disease patients with agitation
J Pharmacokinet Pharmacodyn 2016; 43(1): 99.

1
 
A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer’s disease patients with agitation
J Pharmacokinet Pharmacodyn 2015; (): .

2
 
How to Cite this Article
Pubmed Style

Anjali N Kalore, Dhananjay Medappa, Eukesh Ranjit, Sandeep S Nayak. Safety and Efficacy of Pharmacological Management of Agitation in Alzheimer’s Dementia - A Review. IJHRS. 2015; 4(1): 65-72. doi:10.5455/ijhrs.000000073


Web Style

Anjali N Kalore, Dhananjay Medappa, Eukesh Ranjit, Sandeep S Nayak. Safety and Efficacy of Pharmacological Management of Agitation in Alzheimer’s Dementia - A Review. https://www.ijhrs.org/?mno=187847 [Access: August 12, 2022]. doi:10.5455/ijhrs.000000073


AMA (American Medical Association) Style

Anjali N Kalore, Dhananjay Medappa, Eukesh Ranjit, Sandeep S Nayak. Safety and Efficacy of Pharmacological Management of Agitation in Alzheimer’s Dementia - A Review. IJHRS. 2015; 4(1): 65-72. doi:10.5455/ijhrs.000000073



Vancouver/ICMJE Style

Anjali N Kalore, Dhananjay Medappa, Eukesh Ranjit, Sandeep S Nayak. Safety and Efficacy of Pharmacological Management of Agitation in Alzheimer’s Dementia - A Review. IJHRS. (2015), [cited August 12, 2022]; 4(1): 65-72. doi:10.5455/ijhrs.000000073



Harvard Style

Anjali N Kalore, Dhananjay Medappa, Eukesh Ranjit, Sandeep S Nayak (2015) Safety and Efficacy of Pharmacological Management of Agitation in Alzheimer’s Dementia - A Review. IJHRS, 4 (1), 65-72. doi:10.5455/ijhrs.000000073



Turabian Style

Anjali N Kalore, Dhananjay Medappa, Eukesh Ranjit, Sandeep S Nayak. 2015. Safety and Efficacy of Pharmacological Management of Agitation in Alzheimer’s Dementia - A Review. International Journal of Health and Rehabilitation Sciences (IJHRS), 4 (1), 65-72. doi:10.5455/ijhrs.000000073



Chicago Style

Anjali N Kalore, Dhananjay Medappa, Eukesh Ranjit, Sandeep S Nayak. "Safety and Efficacy of Pharmacological Management of Agitation in Alzheimer’s Dementia - A Review." International Journal of Health and Rehabilitation Sciences (IJHRS) 4 (2015), 65-72. doi:10.5455/ijhrs.000000073



MLA (The Modern Language Association) Style

Anjali N Kalore, Dhananjay Medappa, Eukesh Ranjit, Sandeep S Nayak. "Safety and Efficacy of Pharmacological Management of Agitation in Alzheimer’s Dementia - A Review." International Journal of Health and Rehabilitation Sciences (IJHRS) 4.1 (2015), 65-72. Print. doi:10.5455/ijhrs.000000073



APA (American Psychological Association) Style

Anjali N Kalore, Dhananjay Medappa, Eukesh Ranjit, Sandeep S Nayak (2015) Safety and Efficacy of Pharmacological Management of Agitation in Alzheimer’s Dementia - A Review. International Journal of Health and Rehabilitation Sciences (IJHRS), 4 (1), 65-72. doi:10.5455/ijhrs.000000073



Online Submission & Review

Abstracted & Indexed in:

 

  • Budapest Open Access Initiative (BOAI)

  • Directory of Open Access Journals (DOAJ)

  • Directory of Science 

  • GetCITED

  • Google Scholar

  • ICMJE

  • Index Copernicus International (7.43)

  • Index Scholar

  • J - Gate

  • Journal Index

  • Journal TOCs (UK)

  • ResearchBib

  • Scirus (Elsevier)

  • Scopemed

  • Ulrichsweb Global Serials Directory (ProQuest)

  • WHO (HINARI)